AI Article Synopsis
- CD1d-reactive invariant NKT (iNKT) cells play key roles in various human diseases due to their unique immunoregulatory functions.
- The study finds that human CD161(+) iNKT cells can produce IL-17, but need specific cytokines like TGF-β, IL-1β, and IL-23 for this process, and they are present even in cord blood.
- Unlike other immune cells, IL-17-producing iNKT cells cannot make IFN-γ and have different regulatory characteristics, needing both a built-in program and a stimulating environment to produce IL-17 effectively.
Article Abstract
CD1d-reactive invariant NKT (iNKT) cells have been implicated in a number of experimental models of human pathologies. Given the scope of their immunoregulatory activities mediated through distinct cytokine patterns, it has been proposed that this functional diversity originates from distinct iNKT subpopulations. In this study, we report that human CD161(+) iNKT cells are intrinsically endowed with the capacity to generate IL-17, but require TGF-β, IL-1β, and IL-23 to carry out this potential. IL-17-producing iNKT cells are already present in cord blood but, in contrast to peripheral blood iNKT cells, they cannot generate IFN-γ. These IL-17 producers respond to aryl hydrocarbon receptor stimulation and express IL-23 receptor and retinoic acid-related orphan receptor C, similar to conventional T helper 17 cells, from which they differ by their restricted ability to coproduce IL-22. In conclusion, IL-17 production by human iNKT cells depends on two critical parameters, namely an intrinsic program and a proinflammatory environment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4049/jimmunol.1003043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!